81
Participants
Start Date
December 31, 2009
Primary Completion Date
March 31, 2012
Study Completion Date
March 31, 2015
Amrubicin
30 mg/m2 IV on Days 1-3 of each 3-week treatment cycle
Carboplatin
AUC=5 IV, Day 1 of each 3-week treatment cycle
Pegfilgrastim
6 mg SQ on Day 4 of each 3 week treatment cycle
Center for Cancer and Blood Disorders, Bethesda
National Capital Clinical Research Consortium, Bethesda
Virginia Cancer Institute, Richmond
Peninsula Cancer Institute, Newport News
South Carolina Oncology Associates, PA, Columbia
Medical Oncology Associates of Augusta, Augusta
Florida Hospital Cancer Institute, Orlando
Watson Clinic Center for Cancer Care and Research, Lakeland
Florida Cancer Specialists, Fort Myers
Tennessee Oncology, PLLC, Nashville
Chattanooga Oncology Hematology Associates, Chattanooga
Family Cancer Center, Collierville
Baptist Hospital East, Louisville
Norton Cancer Institute, Louisville
Oncology Hematology Care, Cincinnati
Grand Rapids Clinical Oncology Program, Grand Rapids
Research Medical Center, Kansas City
Nebraska Methodist Cancer Center, Omaha
Hematology Oncology Clinic, LLP, Baton Rouge
Northeast Arkansas Clinic, Jonesboro
Collaborators (1)
Celgene
INDUSTRY
SCRI Development Innovations, LLC
OTHER